SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ:UTHR) Corporation (NASDAQ:UTHR), a biotechnology firm, announced the election of Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors. Shareholders elected Ms. Malcolm during the company's annual meeting on June 26, 2024.
With a background in health policy, public health, and healthcare finance, Malcolm has been recognized for her efforts in addressing health disparities and the social determinants of health. Her leadership was particularly noted during her time as Health Commissioner in the COVID-19 pandemic, where she was instrumental in expanding testing capacity and developing systems for data sharing in Minnesota.
Malcolm's career also includes significant healthcare operational experience, having served as vice president of Allina Health system and CEO of the Courage Center, a rehabilitation and health service provider for people with disabilities.
Martine Rothblatt, Ph.D., Chairperson and CEO of United Therapeutics, expressed confidence that Malcolm's "deep healthcare operational experience" and her "leadership experience in public health and government" will contribute to the company's mission to revolutionize the treatment of end-stage organ disease.
Malcolm, who holds a bachelor's degree from Dartmouth College, stated her enthusiasm for supporting United Therapeutics' mission to meet the critical medical needs of patients with rare lung diseases and other end-stage organ diseases.
Christopher Causey, Chairman of the Nominating and Governance Committee, noted that Malcolm's addition to the board is part of ongoing efforts to introduce new skills and perspectives in line with the company's patient-centric public benefit purpose.
Malcolm succeeds Professor Katherine Klein, who served on the board for a decade and chose not to stand for re-election. Christopher Patusky, Lead Independent Director and Vice Chair, thanked Klein for her contributions during a period of significant growth for United Therapeutics.
United Therapeutics, a public benefit corporation, focuses on developing pharmaceutical therapies and technologies to increase the availability of transplantable organs. This announcement is based on a press release statement from United Therapeutics Corporation.
In other recent news, United Therapeutics Corp . has been in the spotlight due to its strong first-quarter performance, and changes in analyst ratings. The biotechnology company reported a significant 34% year-over-year revenue growth in the first quarter of 2024, exceeding expectations. The growth was driven by the performance of its drug Tyvaso and the impact of the Inflation Reduction Act's Medicare Part D redesign, leading to increased commercial drug utilization.
In response to these developments, Oppenheimer maintained its Outperform rating on United Therapeutics shares and raised the target price from $375 to $400. However, BofA Securities revised its price target for United Therapeutics Corp., changing it to $262 from the previous $270, maintaining an Underperform rating on the stock. This adjustment was made following a physician survey on Pulmonary Arterial Hypertension (PAH) and Interstitial Lung Disease (ILD), leading to a change in valuation methodology from net present value analysis to a price-to-earnings (P/E) multiple approach.
United Therapeutics is also advancing in clinical trials and organ manufacturing initiatives, notably in xenotransplantation, and has announced a $1 billion accelerated share repurchase program, expected to conclude by the end of Q3 2024.
InvestingPro Insights
As United Therapeutics Corporation (NASDAQ:UTHR) welcomes Jan Malcolm to its Board of Directors, the company's financial health and market performance continue to show promise. With a market capitalization of $14.15 billion, United Therapeutics is positioned as a significant player in the biotechnology industry. The company's impressive gross profit margin of 88.87% over the last twelve months as of Q1 2024 underscores its operational efficiency and ability to generate substantial earnings from its revenue.
The company's strategic financial management is evident from an InvestingPro Tip that highlights United Therapeutics' aggressive share buyback strategy, which can often signal a management's confidence in the company's prospects and a commitment to delivering shareholder value. Additionally, the company's strong balance sheet is reflected by another InvestingPro Tip, revealing that United Therapeutics holds more cash than debt, providing financial flexibility and stability.
Investors looking at the company's valuation metrics will find a P/E ratio of 14.23, which is relatively low considering the near-term earnings growth, suggesting that the stock may be undervalued. Moreover, with a robust return on assets of 16.36% for the same period, United Therapeutics demonstrates effective utilization of its assets to generate profits.
For those interested in further insights, InvestingPro offers additional tips on United Therapeutics, which can be accessed by visiting https://www.investing.com/pro/UTHR. Users can take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of data and analysis that can inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.